# A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

> **NCT07017816** · EARLY_PHASE1 · RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 18 (estimated)

## Conditions studied

- CNS Malignancies
- Medulloblastoma Recurrent
- ATRT Recurrent
- Pineoblastoma
- Embryonal Neoplasm
- Ependymoma Recurrent
- High Grade Gliomas

## Interventions

- **DRUG:** SGT-53
- **RADIATION:** hypofractionated radiotherapy with immunotherapy
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07017816
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-16
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017816, "A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07017816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*